Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease
- Tal Marshanski
- , Eliana Fanous
- , Noa Tal
- , Tsachi T. Perets
- , Manar Matar
- , Yael Weintraub
- , Raanan Shamir
- , Dror S. Shouval*
*Corresponding author for this work
- Schneider Childrens Medical Center Israel
- Rabin Medical Center Israel
- Holon Institute of Technology
- Tel Aviv University
Research output: Contribution to journal › Article › peer-review
1
Scopus
citations